Zi-Qing Tang
Biographic Data
| ID | 9999072 |
|---|---|
| NAME | Zi-Qing Tang |
| GIVEN NAMES | Zi-Qing |
| FAMILY NAME | Tang |
| SIGNATURE | TANG Z |
| AFFILIATIONS | Central South University |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
Background: The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM. The study is aim to evaluate the cost-effectiveness of Nivolumab plus ipilimumab vs. platinum plus chemotherapy for the first-line treatment of unresectable MPM. Methods: A Markov model was deve…
No prominent works on this page.
Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
Background: The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM. The study is aim to evaluate the cost-effectiveness of Nivolumab plus ipilimumab vs. platinum plus chemotherapy for the first-line treatment of unresectable MPM. Methods: A Markov model was deve…
Cancer (1 work) · Cancer Immunotherapy and Biomarkers (1 work) · Chemotherapy (1 work) · Cost effectiveness (1 work) · First line treatment (1 work) · Immunotherapy (1 work) · Internal Medicine (1 work) · Ipilimumab (1 work) · Medicine (1 work) · Mesothelioma (1 work)